Active substance
Promazine
- US FDA 6
- UK MHRA 8
- NHS prices 4
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SPARINE | 50MG/ML; 25MG/ML | injectable · injection | HIKMA | Discontinued | 13 Apr 1956 |
| SPARINE | 25MG; 50MG; 100MG; 200MG; 10MG | tablet · oral | WYETH AYERST | Discontinued | 8 Apr 1957 |
| SPARINE | 30MG/ML; 100MG/ML | concentrate · oral | WYETH AYERST | Discontinued | 12 Nov 1957 |
| SPARINE | 10MG/5ML | syrup · oral | WYETH AYERST | Discontinued | 12 Nov 1957 |
| PROMAZINE HYDROCHLORIDE | 25MG/ML | injectable · injection | WATSON LABS | Discontinued | |
| PROMAZINE HYDROCHLORIDE | 50MG/ML | injectable · injection | WATSON LABS | Discontinued |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| PROMAZINE 25MG TABLETS | PL 00289/0798 | TEVA UK LIMITED | POM |
| PROMAZINE 25MG/5ML ORAL SYRUP | PL 00427/0054 | ROSEMONT PHARMACEUTICALS LIMITED | POM |
| PROMAZINE 50MG TABLETS | PL 00289/0799 | TEVA UK LIMITED | POM |
| PROMAZINE 50MG/5ML ORAL SYRUP | PL 00427/5014R | ROSEMONT PHARMACEUTICALS LIMITED | POM |
| PROMAZINE HYDROCHLORIDE 25 MG/5 ML ORAL SYRUP | PL 40546/0178 | ARISTO PHARMA GMBH | POM |
| PROMAZINE HYDROCHLORIDE 25 MG/5 ML ORAL SYRUP | PL 58839/0070 | ZYDUS PHARMACEUTICALS UK LTD | POM |
| PROMAZINE HYDROCHLORIDE 50 MG/5 ML ORAL SYRUP | PL 40546/0179 | ARISTO PHARMA GMBH | POM |
| PROMAZINE HYDROCHLORIDE 50 MG/5 ML ORAL SYRUP | PL 58839/0071 | ZYDUS PHARMACEUTICALS UK LTD | POM |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Promazine 25mg tablets | £86.24 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Promazine 25mg/5ml oral solution | £79.50 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Promazine 50mg tablets | £137.83 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Promazine 50mg/5ml oral solution | £102.24 | 150 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.